Invesco’s Minerva Neurosciences NERV Stock Holding History

Invesco’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-15,330	Closed	-$1.44M	–	3734
2016 Q4	$1.44M	Buy	+15,330	New	+$1.56M	﹤0.01%	2808

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco's NERV Position: Q1 2017 in Review

Invesco sold out of Minerva Neurosciences (NERV) in Q1 2017, closing a stake of 15,330 shares — an estimated $1.44M sold.

Invesco first reported a position in NERV in Q4 2016 and held it in 1 quarter. The position peaked at $1.44M in Q4 2016. 71 funds tracked by Wall St. Rank hold NERV as of Q1 2017.

Invesco reported no remaining Minerva Neurosciences position as of Q1 2017 after selling out during the quarter.
Invesco sold 15,330 Minerva Neurosciences shares in Q1 2017, an estimated $1.44M.
Invesco first reported a position in Minerva Neurosciences in Q4 2016 and held it in 1 quarter.
Invesco's Minerva Neurosciences position peaked at $1.44M in Q4 2016.
71 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2017.

Based on Invesco's 13F filing for Q1 2017, filed 15 May 2017.